FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281788912> ?p ?o ?g. }

• W4281788912 abstract "Abstract Background Chimeric antigen receptor (CAR)-T cells can induce powerful immune responses in patients with hematological malignancies but have had limited success against solid tumors. This is in part due to the immunosuppressive tumor microenvironment (TME) which limits the activity of tumor-infiltrating lymphocytes (TILs) including CAR-T cells. We have developed a next-generation armored CAR (F i-CAR) targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), which is expressed at high levels in a range of aggressive tumors including poorly prognostic triple-negative breast cancer (TNBC). The F i-CAR-T is designed to release an anti-PD-1 checkpoint inhibitor upon CAR-T cell activation within the TME, facilitating activation of CAR-T cells and TILs while limiting toxicity. Methods To bolster potency, we developed a F i-CAR construct capable of IL-2-mediated, NFAT-induced secretion of anti-PD-1 single-chain variable fragments (scFv) within the tumor microenvironment, following ROR1-mediated activation. Cytotoxic responses against TNBC cell lines as well as levels and binding functionality of released payload were analyzed in vitro by ELISA and flow cytometry. In vivo assessment of potency of F i-CAR-T cells was performed in a TNBC NSG mouse model. Results F i-CAR-T cells released measurable levels of anti-PD-1 payload with 5 h of binding to ROR1 on tumor and enhanced the cytotoxic effects at challenging 1:10 E:T ratios. Treatment of established PDL1 + TNBC xenograft model with F i-CAR-T cells resulted in significant abrogation in tumor growth and improved survival of mice (71 days), compared to non-armored CAR cells targeting ROR1 (F CAR-T) alone (49 days) or in combination with systemically administered anti-PD-1 antibody (57 days). Crucially, a threefold increase in tumor-infiltrating T cells was observed with F i-CAR-T cells and was associated with increased expression of genes related to cytotoxicity, migration and proliferation. Conclusions Our next-generation of ROR1-targeting inducible armored CAR platform enables the release of an immune stimulating payload only in the presence of target tumor cells, enhancing the therapeutic activity of the CAR-T cells. This technology provided a significant survival advantage in TNBC xenograft models. This coupled with its potential safety attributes merits further clinical evaluation of this approach in TNBC patients." @default.
• W4281788912 created "2022-06-13" @default.
• W4281788912 creator A5013238164 @default.
• W4281788912 creator A5032635874 @default.
• W4281788912 creator A5045437232 @default.
• W4281788912 creator A5050429452 @default.
• W4281788912 creator A5050731553 @default.
• W4281788912 creator A5052659347 @default.
• W4281788912 creator A5058521816 @default.
• W4281788912 creator A5058626201 @default.
• W4281788912 creator A5066475421 @default.
• W4281788912 creator A5067138070 @default.
• W4281788912 creator A5082063678 @default.
• W4281788912 creator A5089455737 @default.
• W4281788912 date "2022-06-03" @default.
• W4281788912 modified "2023-10-17" @default.
• W4281788912 title "Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC" @default.
• W4281788912 cites W1576457524 @default.
• W4281788912 cites W2345415641 @default.
• W4281788912 cites W2556226634 @default.
• W4281788912 cites W2560367415 @default.
• W4281788912 cites W2612649234 @default.
• W4281788912 cites W2615287735 @default.
• W4281788912 cites W2773804840 @default.
• W4281788912 cites W2792105646 @default.
• W4281788912 cites W2886131798 @default.
• W4281788912 cites W2966505016 @default.
• W4281788912 cites W2986629061 @default.
• W4281788912 cites W3005412445 @default.
• W4281788912 cites W3014160477 @default.
• W4281788912 doi "https://doi.org/10.1186/s13058-022-01531-1" @default.
• W4281788912 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35659040" @default.
• W4281788912 hasPublicationYear "2022" @default.
• W4281788912 type Work @default.
• W4281788912 citedByCount "8" @default.
• W4281788912 countsByYear W42817889122023 @default.
• W4281788912 crossrefType "journal-article" @default.
• W4281788912 hasAuthorship W4281788912A5013238164 @default.
• W4281788912 hasAuthorship W4281788912A5032635874 @default.
• W4281788912 hasAuthorship W4281788912A5045437232 @default.
• W4281788912 hasAuthorship W4281788912A5050429452 @default.
• W4281788912 hasAuthorship W4281788912A5050731553 @default.
• W4281788912 hasAuthorship W4281788912A5052659347 @default.
• W4281788912 hasAuthorship W4281788912A5058521816 @default.
• W4281788912 hasAuthorship W4281788912A5058626201 @default.
• W4281788912 hasAuthorship W4281788912A5066475421 @default.
• W4281788912 hasAuthorship W4281788912A5067138070 @default.
• W4281788912 hasAuthorship W4281788912A5082063678 @default.
• W4281788912 hasAuthorship W4281788912A5089455737 @default.
• W4281788912 hasBestOaLocation W42817889121 @default.
• W4281788912 hasConcept C121608353 @default.
• W4281788912 hasConcept C126322002 @default.
• W4281788912 hasConcept C154317977 @default.
• W4281788912 hasConcept C185592680 @default.
• W4281788912 hasConcept C202751555 @default.
• W4281788912 hasConcept C203014093 @default.
• W4281788912 hasConcept C2776090121 @default.
• W4281788912 hasConcept C2776107976 @default.
• W4281788912 hasConcept C2777701055 @default.
• W4281788912 hasConcept C2780110267 @default.
• W4281788912 hasConcept C2780674031 @default.
• W4281788912 hasConcept C2780851360 @default.
• W4281788912 hasConcept C3875195 @default.
• W4281788912 hasConcept C502942594 @default.
• W4281788912 hasConcept C530470458 @default.
• W4281788912 hasConcept C55493867 @default.
• W4281788912 hasConcept C71924100 @default.
• W4281788912 hasConcept C8891405 @default.
• W4281788912 hasConceptScore W4281788912C121608353 @default.
• W4281788912 hasConceptScore W4281788912C126322002 @default.
• W4281788912 hasConceptScore W4281788912C154317977 @default.
• W4281788912 hasConceptScore W4281788912C185592680 @default.
• W4281788912 hasConceptScore W4281788912C202751555 @default.
• W4281788912 hasConceptScore W4281788912C203014093 @default.
• W4281788912 hasConceptScore W4281788912C2776090121 @default.
• W4281788912 hasConceptScore W4281788912C2776107976 @default.
• W4281788912 hasConceptScore W4281788912C2777701055 @default.
• W4281788912 hasConceptScore W4281788912C2780110267 @default.
• W4281788912 hasConceptScore W4281788912C2780674031 @default.
• W4281788912 hasConceptScore W4281788912C2780851360 @default.
• W4281788912 hasConceptScore W4281788912C3875195 @default.
• W4281788912 hasConceptScore W4281788912C502942594 @default.
• W4281788912 hasConceptScore W4281788912C530470458 @default.
• W4281788912 hasConceptScore W4281788912C55493867 @default.
• W4281788912 hasConceptScore W4281788912C71924100 @default.
• W4281788912 hasConceptScore W4281788912C8891405 @default.
• W4281788912 hasFunder F4320307874 @default.
• W4281788912 hasFunder F4320310960 @default.
• W4281788912 hasFunder F4320320104 @default.
• W4281788912 hasIssue "1" @default.
• W4281788912 hasLocation W42817889121 @default.
• W4281788912 hasLocation W42817889122 @default.
• W4281788912 hasLocation W42817889123 @default.
• W4281788912 hasLocation W42817889124 @default.
• W4281788912 hasLocation W42817889125 @default.
• W4281788912 hasLocation W42817889126 @default.
• W4281788912 hasOpenAccess W4281788912 @default.
• W4281788912 hasPrimaryLocation W42817889121 @default.
• W4281788912 hasRelatedWork W2248619413 @default.
• W4281788912 hasRelatedWork W2803061034 @default.

• next